Funding
Funding not disclosed
Founders
Product
Problem
Biotech teams developing engineered strains often face slow progress and high production costs because traditional optimization methods miss many genetic modification opportunities, both predicted and unexpected.
Solution
FinishLine Bio offers a proprietary, curated database that aggregates cutting‑edge research and validated optimization targets to reveal both predicted and hidden genetic modification sites. By providing insights for enzymes, promoters, and host strains, the platform enables faster identification of engineering strategies that can improve pathway performance, strain health, and product yields. Access to this database helps companies accelerate strain development cycles and lower cost of goods, moving projects toward commercial scale more efficiently. Interested users can join a waitlist to receive database access for their specific projects.
Target Audience
Primary customers are biotech companies and research teams focused on metabolic engineering, synthetic biology, and industrial biotechnology who need to optimize microbial strains for commercial production.
Features
- Comprehensive collection of experimentally validated genetic modification targets across enzymes, promoters, and host strains
- Identification of unexpected modification sites that are typically overlooked by conventional approaches
- Continuous integration of the latest research findings to keep the database up‑to‑date
- Searchable interface allowing users to query specific genes, pathways, or organism hosts
- Exportable data formats compatible with common bioinformatics and strain engineering pipelines